| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2025 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.0107 | Jun 30, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0127 | Jun 30, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2025 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 31, 2025 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.01165 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2025 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 28, 2025 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 31, 2025 | Active | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Jan 31, 2025 | Active | N/A |
| Revised Total Coliform Rule | Health-Based | N/A | N/A | Jan 31, 2025 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.01263 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2024 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.01273 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Sep 30, 2024 | Active | N/A |
| E. COLI | Monitoring | 0 | N/A | Jun 30, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| Arsenic | Health-Based | N/A | 0.01163 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.01163 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Jun 30, 2024 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 30, 2024 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 30, 2024 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.01363 | Jun 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 31, 2024 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.01235 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.01235 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.01305 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.01305 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Mar 31, 2024 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.01488 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Mar 31, 2024 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.01128 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.01128 | Mar 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Mar 31, 2024 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 29, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 29, 2024 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 31, 2024 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 31, 2024 | Active | N/A |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrite | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrite | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Arsenic | Health-Based | N/A | 0.01348 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.01348 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Dec 31, 2023 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.0182 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrite | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Arsenic | Health-Based | N/A | 0.01323 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.01323 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Dec 31, 2023 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.01428 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 31, 2023 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrate | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrite | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Nitrite | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Infants below the age of six months could become seriously ill (blue baby syndrome); shortness of breath |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Active | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Active | N/A |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 31, 2023 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.01193 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.01193 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.01193 | Dec 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Sep 30, 2023 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.0132 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0132 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0182 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0126 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0126 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Sep 30, 2023 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.0151 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0117 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0117 | Sep 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2023 | Resolved | N/A |
| E. COLI | Monitoring | 0 | N/A | Jul 31, 2023 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Jul 31, 2023 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Jul 31, 2023 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| Arsenic | Health-Based | N/A | 0.0108 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0108 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0468 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0145 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.012 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0493 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0135 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 28, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 28, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0705 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0133 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Nov 30, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.091 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0128 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0271 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0115 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0118 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0118 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Jun 30, 2022 | Active | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0114 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0119 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0143 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0143 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0177 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0135 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0114 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.0847 | Sep 30, 2021 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.0847 | Sep 30, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0187 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0157 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0114 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0114 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jul 31, 2021 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.1027 | Jun 30, 2021 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.1027 | Jun 30, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0307 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.0175 | Jun 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.1245 | Mar 31, 2021 | Resolved | N/A |
| TTHM | Health-Based | N/A | 0.1245 | Mar 31, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0177 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.0178 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |